Navigation Links
The Johns Hopkins Center for Inherited Disease Research receives $101 million
Date:8/10/2012

The Johns Hopkins Center for Inherited Disease Research (CIDR) program contract, which provides up to $101 million in research funding from the National Institutes of Health (NIH) to study the genetic contribution to human diseases, has been renewed for another five years.

"We are thrilled the NIH has awarded us this contract," says Kimberly Doheny, Ph.D., lead principal investigator of CIDR. "The bulk of the contract support allows us to generate sequencing or genotyping datasets for an average of 30 large genetic studies per year. A separate component of the contract supports the center's infrastructure, including the exploration of new technologies and the extensive IT infrastructure necessary to serve new data-intensive methods, like high-throughput genomic technologies."

CIDR, part of the McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins, is a national resource for genetics researchers. Established in 1996, the center performs DNA genotyping and sequencing to identify genes linked to disease. CIDR also offers statistical genetics consultation to investigators. Researchers at CIDR thus far have analyzed over 620,000 DNA samples and identified genes associated with cancer, addiction, glaucoma, Parkinson's disease and many other genetic diseases.

Doheny, along with David Valle, M.D., Henry J. Knott Professor and director of the Institute of Genetic Medicine, and Alan Scott, Ph.D., will serve as the co-principal investigators of the center.

"CIDR's main goal is to support the genetics community a large group of molecular geneticists and bioinformaticians in their efforts to find genes that contribute to disease," says Valle. "We share our expertise with the Johns Hopkins community and offer fee-for-service access to our facility to all investigators."

The NIH program contract was initially awarded to CIDR in 1996 by the NIH and renewed in 2007 and now again in 2012. The contract receives funding from 14 NIH institutes. Investigators with grants from one of these institutes can apply for access to CIDR's sequencing and genotyping services. If the project is approved, the supporting NIH institute pays for the project directly through the contract. Access to the CIDR resources is also available on a fee-for-use basis through the Johns Hopkins Genetic Resources Core Facility (grcf.jhmi.edu).


'/>"/>

Contact: Vanessa McMains
vmcmain1@jhmi.edu
410-502-9410
Johns Hopkins Medicine
Source:Eurekalert

Related biology news :

1. Johns Hopkins researchers uncover genes at fault for cystic fibrosis-related intestinal obstruction
2. Johns Hopkins researchers link 2 biological risk factors for schizophrenia
3. New Center for Carbon Measurement to drive UKs low carbon economy
4. Israel names Tel Aviv Universitys Renewable Energy Center a Center of Research Excellence
5. Heart study suggests city center pollution doubles risk of calcium build-up in arteries
6. Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship
7. UC Santa Cruz builds national data center for cancer genome research
8. UF to establish Faroe Island research center with help of baseball star
9. DOE Plasma Science Center Annual Meeting at Princeton Plasma Lab
10. UH Case Medical Center, CardioKinetix reveal promising data for treatment for heart failure
11. Tufts Medical Center researchers finds marker in premies saliva predicts readiness to feed by mouth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2020)... ... 2020 , ... Litmus Health , the research-ready infrastructure ... the company’s security practices has been completed. The assessment deemed Litmus infrastructure to ... reviewed Litmus’ processes and systems, assessing them to see whether they adhere to ...
(Date:8/26/2020)... (PRWEB) , ... August 25, ... ... clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex ... enrolment in its pivotal U.S. Phase 3 VISTA-2 study of SkQ1 ophthalmic ...
(Date:8/26/2020)... ... ... Modality Solutions, a biopharmaceutical cold chain validation engineering firm, is pleased to ... most prestigious ranking of the nation’s fastest-growing private companies. Modality Solutions made the Inc. ... growth of 71 percent. , The Inc. 5000 list represents a unique look ...
Breaking Biology News(10 mins):
(Date:8/31/2020)... (PRWEB) , ... August 29, 2020 , ... ... new Animal Nutrition manufacturing capability in Wuxi, China. The new plant operation will ... quality standards and advanced technology. , “This facility will improve the flexibility ...
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD Society announced ... Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration of follow-on ... consortium of academic research centers in the United States and Europe with expertise ...
(Date:8/7/2020)... ... August 06, 2020 , ... VGXI, a ... has closed on the purchase of greenfield for a new, expanded manufacturing facility. ... over 21 acres in the initial acquisition, with an option to purchase an ...
(Date:7/31/2020)... ... 2020 , ... R3 Stem Cell International is now offering patients the opportunity ... cells total, patients may choose which extremities they would like treated. , Several studies ... Disord. 2016). At R3 International, umbilical cord tissue is obtained from a lab with ...
Breaking Biology Technology: